Connect Biopharma Total Debt vs. Return On Equity
| CNTB Stock | USD 0.97 0.01 1.02% |
For Connect Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Connect Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Connect Biopharma Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Connect Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Connect Biopharma Holdings over time as well as its relative position and ranking within its peers.
Connect |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.39) | Revenue Per Share 0.438 | Return On Assets (0.12) | Return On Equity (0.18) |
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Connect Biopharma Return On Equity vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Connect Biopharma's current stock value. Our valuation model uses many indicators to compare Connect Biopharma value to that of its competitors to determine the firm's financial worth. Connect Biopharma Holdings is rated below average in total debt category among its peers. It is number one stock in return on equity category among its peers . At present, Connect Biopharma's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Connect Biopharma's earnings, one of the primary drivers of an investment's value.Connect Total Debt vs. Competition
Connect Biopharma Holdings is rated below average in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 146.13 Million. Connect Biopharma adds roughly 465,000 in total debt claiming only tiny portion of equities under Health Care industry.
Connect Return On Equity vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Connect Biopharma |
| = | 465 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Connect Biopharma |
| = | -0.18 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Connect Return On Equity Comparison
Connect Biopharma is currently under evaluation in return on equity category among its peers.
Connect Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Connect Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Connect Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Connect Biopharma's change in net profit over the period of time. It can combine multiple indicators of Connect Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 11.9 M | 12.4 M | |
| Net Loss | -1.2 B | -1.1 B | |
| Net Interest Income | 2.7 M | 2.8 M | |
| Interest Income | 2.7 M | 3.5 M | |
| Operating Income | -62.1 M | -65.2 M | |
| Net Loss | -59.5 M | -62.5 M | |
| Income Before Tax | -59.4 M | -62.4 M | |
| Total Other Income Expense Net | 2.7 M | 2.8 M | |
| Net Loss | -59.4 M | -62.4 M | |
| Income Tax Expense | 120 K | 126 K | |
| Change To Netincome | 847.5 M | 889.9 M | |
| Net Loss | (1.08) | (1.13) | |
| Income Quality | 0.81 | 0.46 | |
| Net Income Per E B T | 1.00 | 0.80 |
Connect Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Connect Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Connect Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Connect Biopharma's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Connect Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run USA ETFs Now
USA ETFsFind actively traded Exchange Traded Funds (ETF) in USA |
| All Next | Launch Module |
Use Investing Themes to Complement your Connect Biopharma position
In addition to having Connect Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Entertainment Thematic Idea Now
Entertainment
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Entertainment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Entertainment Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
To fully project Connect Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Connect Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Connect Biopharma's income statement, its balance sheet, and the statement of cash flows.